Recent advancements in stem cell technology open a new door for patients suffering from
diseases and disorders that have yet to be treated. Stem cell-based therapy, including …

Although the treatment of myocardial infarction (MI) has improved considerably, it is still a
worldwide disease with high morbidity and high mortality. Whilst there is still a long way to …

Cardiovascular diseases are a leading cause of death worldwide. Current treatments
directed at heart repair have several disadvantages, such as a lack of donors for heart …

Upon myocardial infarction (MI), activated cardiac fibroblasts (CFs) begin to remodel the
myocardium, leading to cardiac fibrosis and even heart failure. No therapeutic approaches …

Tissue Engineering (TE) is a branch of Regenerative Medicine (RM) that combines stem
cells and biomaterial scaffolds to create living tissue constructs to restore patients' organs …

Transplantation of mesenchymal stem cells (MSCs) in the setting of cardiovascular disease,
such as heart failure, cardiomyopathy and ischemic heart disease, has been associated with …

Exosomes, which contain miRNA, have been receiving growing attention in cardiovascular
therapy because of their role in mediating cell-cell communication, autophagy, apoptosis …

Tissue engineering has paved the way for the development of artificial human cardiac
muscle patches (hCMPs) and cardiac tissue analogs, especially for treating Myocardial …

Ischemic heart disease (IHD) is the leading cause of morbidity and mortality worldwide.
Ischemia and hypoxia following myocardial infarction (MI) cause subsequent cardiomyocyte …

Background: Acute myocardial infarction (AMI) is a leading cause of death and disability.
Diabetes is an important risk factor and a common comorbidity in AMI patients. The higher …